BidaskClub cut shares of Pulse Biosciences (NASDAQ:PLSE) from a sell rating to a strong sell rating in a research report report published on Wednesday morning.
Separately, ValuEngine raised Pulse Biosciences from a sell rating to a hold rating in a research report on Friday, February 2nd.
Pulse Biosciences (NASDAQ PLSE) opened at $18.82 on Wednesday. The firm has a market capitalization of $310.16, a price-to-earnings ratio of -13.54 and a beta of -0.17. Pulse Biosciences has a 52-week low of $9.81 and a 52-week high of $39.50.
In other news, Director Maky Zanganeh bought 4,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 12th. The shares were acquired at an average cost of $23.07 per share, with a total value of $92,280.00. Following the transaction, the director now owns 332,500 shares of the company’s stock, valued at approximately $7,670,775. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 6.70% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of the stock. Citadel Advisors LLC purchased a new position in shares of Pulse Biosciences in the 4th quarter worth $7,975,000. Vanguard Group Inc. raised its position in shares of Pulse Biosciences by 49.7% in the 2nd quarter. Vanguard Group Inc. now owns 267,810 shares of the company’s stock worth $9,247,000 after buying an additional 88,902 shares during the period. State Street Corp purchased a new position in shares of Pulse Biosciences in the 2nd quarter worth $4,538,000. Northern Trust Corp raised its position in Pulse Biosciences by 859.3% in the second quarter. Northern Trust Corp now owns 97,554 shares of the company’s stock valued at $3,369,000 after purchasing an additional 87,385 shares during the period. Finally, Wells Fargo & Company MN raised its position in Pulse Biosciences by 13.8% in the third quarter. Wells Fargo & Company MN now owns 61,398 shares of the company’s stock valued at $1,143,000 after purchasing an additional 7,465 shares during the period. 9.27% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This report was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another publication, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/02/17/pulse-biosciences-plse-cut-to-strong-sell-at-bidaskclub.html.
About Pulse Biosciences
Pulse Biosciences, Inc, formerly Electroblate, Inc, is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue.
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.